Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study
· Analyses of safety, functionality and user acceptance was positive · Reported decrease in anxiety scores for patients with pulmonary fibrosis · COMPANION, a pivotal study in 250 patients with pulmonary fibrosis, to be initiated in Q4 2022 Gothenburg, October 6, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”) pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive results for the pilot phase of the COMPANION study. Vicore’s digital Cognitive Behavioral Therapy (CBT) therapy, Almee[TM]; for patients with pulmonary fibrosis was safe,